Targeting HER2 amplifications in metastatic colorectal cancer: searching for the most active combination therapy?
Mixed results from the the HERACLES-B, TRIUMPH and MOUNTAINEER trials
Clinical benefits from antibody–drug conjugates are reported for bladder cancer
At ESMO 2019, early clinical data from two studies show the promise of this new generation of treatments although not yet practice-changing
Precision medicine bursts onto the biliary tract cancer scene
The management of biliary tract cancers, especially cholangiocarcinoma, is rapidly changing with emerging new precision medicine strategies